399 related articles for article (PubMed ID: 13678738)
21. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
24. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
25. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Tewari D; Java JJ; Salani R; Armstrong DK; Markman M; Herzog T; Monk BJ; Chan JK
J Clin Oncol; 2015 May; 33(13):1460-6. PubMed ID: 25800756
[TBL] [Abstract][Full Text] [Related]
26. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
27. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
28. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.
Barakat RR; Sabbatini P; Bhaskaran D; Revzin M; Smith A; Venkatraman E; Aghajanian C; Hensley M; Soignet S; Brown C; Soslow R; Markman M; Hoskins WJ; Spriggs D
J Clin Oncol; 2002 Feb; 20(3):694-8. PubMed ID: 11821450
[TBL] [Abstract][Full Text] [Related]
30. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients.
Romanini A; Tanganelli L; Carnino F; Fanucchi A; Lionetto R; Pastorino S; Cosio S; Gadducci A; Conte PF
Gynecol Oncol; 2003 Jun; 89(3):354-9. PubMed ID: 12798695
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
Richard SD; Sukumvanich P; Lesnock JL; McBee WC; Beriwal S; Edwards RP; Zorn KK; Krivak TC
Int J Gynecol Cancer; 2010 Aug; 20(6):932-5. PubMed ID: 20683398
[TBL] [Abstract][Full Text] [Related]
33. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
34. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
[TBL] [Abstract][Full Text] [Related]
37. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
[TBL] [Abstract][Full Text] [Related]
38. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
39. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Cancer; 2002 Apr; 94(7):1961-7. PubMed ID: 11932898
[TBL] [Abstract][Full Text] [Related]
40. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
Polyzos A; Tsavaris N; Kosmas C; Giannikos L; Katsikas M; Kalahanis N; Karatzas G; Christodoulou K; Giannakopoulos K; Stamatiadis D; Katsilambros N
Oncology; 1999; 56(4):291-6. PubMed ID: 10343192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]